

Causal Effects Contributing to Elevated Metabolic Power During Walking in Children Diagnosed with Cerebral Palsy

1 Pavreet K. Gill¹, Katherine M. Steele², J. Maxwell Donelan¹, & Michael H. Schwartz^{3,4}

2 ¹ Locomotion Lab, Simon Fraser University, Department of Biomedical Physiology & Kinesiology,
3 Burnaby, BC, Canada

4 ² Ability and Innovation Lab, University of Washington, Department of Mechanical Engineering,
5 Seattle, WA, USA

6 ³ Gillette Children's Specialty Healthcare, MN, USA

7 ⁴ University of Minnesota, Department of Orthopedic Surgery, MN, USA

8 * **Correspondence:**

9 Pavreet Gill

10 pavreet_gill@sfu.ca

11 **Keywords: Cerebral palsy; Walking; Causal diagrams; Energy; Bayesian; Children**

12 **Abstract**

13 Metabolic power (net energy consumed while walking per unit time) is, on average, two-to-three
14 times greater in children with cerebral palsy (CP) than their typically developing peers, contributing
15 to greater physical fatigue, lower levels of physical activity and greater risk of cardiovascular disease.
16 The goal of this project was to identify the total causal effects of clinical factors that may contribute
17 to high metabolic power demand in children with CP.

18 We included children who 1) visited Gillette Children's Specialty Healthcare for a quantitative gait
19 assessment after the year 2000, 2) were formally diagnosed with CP, 3) were classified as level I-III
20 under the Gross Motor Function Classification System and 4) were 18 years old or younger. We
21 created a structural causal model that specified the assumed relationships of a child's gait pattern
22 (i.e., gait deviation index, GDI) and common impairments (i.e., dynamic and selective motor control,
23 strength, and spasticity) with metabolic power. We estimated causal effects using Bayesian additive
24 regression trees, adjusting for factors identified by the causal model.

25 There were 2157 children who met our criteria. We found that a child's gait pattern, as summarized
26 by the GDI, affected metabolic power approximately twice as much as the next largest contributor.
27 Selective motor control, dynamic motor control, and spasticity had the next largest effects. Among
28 the factors we considered, strength had the smallest effect on metabolic power.

29 Our results suggest that children with CP may benefit more from treatments that improve their gait
30 pattern and motor control than treatments that improve spasticity or strength.

31

Contributors to High Metabolic Power in CP

32 1 Introduction

33 The net metabolic power required during walking is, on average, two-to-three times greater in
34 children with cerebral palsy (CP) than their typically developing peers (Campbell and Ball, 1978;
35 Rose et al., 1990). As a result, walking is as difficult as performing moderate- to vigorous-intensity
36 exercise (Balemans et al., 2017). Net metabolic power during walking (metabolic power) is the
37 metabolic energy consumed while walking minus the metabolic energy consumed while resting per
38 unit time. High metabolic power contributes to greater physical fatigue (Jahnsen et al., 2007;
39 Balemans et al., 2017), lower physical activity (Carlon et al., 2013; Ryan et al., 2014), increased risk
40 of cardiovascular disease (Hammam et al., 2021), and reduced participation in school and the
41 community (Verschuren et al., 2012). Reducing or preventing fatigue is one of the top research
42 priorities of the CP community (Gross et al., 2018) and reducing metabolic power is a mechanism by
43 which to do so.

44 Due to brain injury near the time of birth, children with CP exhibit various neurological impairments
45 that may contribute to high metabolic power. Spasticity is present in up to 91% of children with CP
46 (Odding et al., 2006) and clinicians often believe it causes high metabolic power via inappropriate or
47 prolonged muscle contraction and co-contraction of agonists and antagonists. However, several
48 recent studies have indicated that spasticity reduction does not cause meaningful reductions in
49 metabolic power during walking (Ubhi et al., 2000; Thomas et al., 2004; Bjornson et al., 2007;
50 Munger et al., 2017; Zaino et al., 2020). Reduced metabolic power following spasticity treatment in
51 observational settings likely arises from other factors such as aging. In addition to spasticity, muscle
52 weakness and poor motor control are also common neurological impairments in CP. Both may
53 contribute to high metabolic power via inefficient muscle activation and altered gait mechanics
54 (Damiano et al., 2000; Rose and McGill, 2007; Bennett et al., 2012; Steele et al., 2015; Schwartz et
55 al., 2016), but they are inextricably linked, so it is challenging to isolate their effects. Conner et al.
56 (2020) recently showed that resistance training via ankle exoskeletons significantly improved muscle
57 strength and reduced metabolic power in children with CP. Further, their exoskeleton training also
58 caused significant improvements in motor control and walking mechanics (Conner et al., 2021). Prior
59 studies of resistance training have demonstrated mixed results (MacPhail and Kramer, 1995;
60 Damiano and Abel, 1998; Eagleton et al., 2004; Ryan et al., 2020), suggesting that muscle weakness
61 may also be a cause of high metabolic power. Understanding the relative effects of strength, motor
62 control, and other factors on high metabolic power in CP is challenging, but important to understand
63 and reduce these demands.

64 In addition to neurological impairments, children with CP also exhibit atypical gait kinematics that
65 may contribute to high metabolic power. Bony malalignments are common in CP and contribute to
66 altered gait kinematics. Many children undergo orthopedic surgery to correct these malalignments
67 and display significantly improved gait kinematics post-treatment. However, no controlled study has
68 directly investigated whether changes in gait kinematics after surgery – in contrast to other factors
69 such as aging – cause significant reductions in metabolic power. For example, McMulkin et al.,
70 (2016) assessed surgical outcomes for children undergoing multi-level surgery with and without a
71 femoral derotation osteotomy. In this study, treatment and control groups were matched except for
72 the inclusion of a femoral derotation osteotomy. McMulkin’s study showed that a femoral derotation
73 osteotomy results in slightly better outcomes after surgery (McMulkin et al., 2016), but was not able
74 to show that better gait kinematics cause lower metabolic power since both groups underwent near-
75 identical treatments and experienced similar changes in gait kinematics. Similar studies provide
76 further insights into how gait kinematics and metabolic power change after surgery (Thomas et al.,

Contributors to High Metabolic Power in CP

77 2004; Wren et al., 2013), but cannot address this central question of whether improved kinematics
78 lowers the metabolic power required to walk.

79 Currently, experimental data does not clearly refute or confirm various factors as causes of high
80 metabolic power in CP. The gold standard for making causal inferences is to perform controlled
81 experiments, where all other factors except the factor of interest are kept constant. However,
82 controlled experiments are not always possible. For example, it is not possible to keep kinematics
83 and kinetics constant while changing muscle spasticity. In place of experimental data, we may be
84 able to analyze the natural variability present in observational data to understand what factors are
85 responsible for high metabolic power and their relative effect sizes.

86 Researchers often hesitate to make causal inferences from observational data due to confounding.
87 Two things are needed to infer causation – the "cause" must occur before the "effect" (temporal
88 priority) and all other "potential causes" (confounders) must be controlled for. Confounding is
89 common in observational studies since data are collected in uncontrolled environments. We can
90 reduce confounding by statistically controlling (adjusting) for factors, but we may induce bias if we
91 fail to do so correctly. MacWilliams and colleagues have shown that without appropriate adjustment,
92 linear regression analysis can greatly over or underestimate effect sizes for factors causing function
93 limitations in CP (MacWilliams et al., 2020). If we can correctly identify confounders, causal
94 inferences are possible (Pearl, 1995).

95 Causal models provide a systematic approach to identifying confounders. One type of causal model
96 is the structural causal model, often depicted as a directed acyclic graph. A directed acyclic graph is a
97 graphical representation of causal relationships that can be queried to determine possible confounders
98 (Pearl, 1995). Directed acyclic graphs are easier to use and less likely to fail at identifying
99 confounders compared to traditional methods (Hernán and Robins, 2020), enabling causal inferences
100 from observational data.

101 In the study described here, we (1) propose a causal model for metabolic power in CP as a function
102 of gait kinematics, selective motor control, dynamic motor control, strength, and spasticity, and (2)
103 compute the total causal effect of each factor on metabolic power with large scale data. We decided
104 to investigate these five factors as they are commonly measured or treated and likely contribute to
105 high metabolic power in children with CP. We used directed acyclic graphs to form our causal model
106 and identify confounders. Then, we used Bayesian additive regression trees (BART) to compute the
107 causal effects of these five factors, including model-identified confounders in the analysis to adjust
108 for their effects.

109 **2 Materials and Methods**

110 **2.1 Participants**

111 We obtained approval for this research from the Research Ethics Board (REB) at Simon Fraser
112 University.

113 We retrospectively analyzed data collected from 6220 children seen between the years 2000 and
114 2020 at the Center for Gait and Motion Analysis at Gillette Children's Specialty Healthcare. We
115 selected children who met the following criteria: formally diagnosed with CP; classified as level I, II,
116 or III under the Gross Motor Function Classification System (GMFCS); 18 years or younger; and had
117 undergone a quantitative 3D gait assessment and a 6-minute walking metabolic assessment. Many

Contributors to High Metabolic Power in CP

118 children had visited the lab more than once. To avoid pseudoreplication, we selected the visit with
119 the least missing data.

120 2.2 Data Collection

121 Spasticity was measured by a trained physical therapist using the Ashworth Scale (Bohannon and
122 Smith, 1987; Pandyan et al., 1999). The Ashworth scale is a 5-point scale defined by the following:
123 (1) no increase in tone, (2) slight increase in tone, (3) more marked increase in tone, (4) considerable
124 increase in tone, and (5) rigidity. Six muscle groups were assessed bilaterally: hip flexors, hip
125 adductors, rectus femoris, hamstrings, plantarflexors, and tibialis posterior. We calculated a summary
126 spasticity score by applying polychoric principal component analysis to the bilateral measurements
127 from these six muscles for individuals with complete data (Rozumalski and Schwartz, 2009; Zaino et
128 al., 2020). We used polychoric principal component analysis since standard principal component
129 analysis produces biased estimates with categorical data (Kolenikov and Angeles, 2009).

130 Strength was measured by a physical therapist for the hip flexors, hip adductors, rectus femoris,
131 hamstrings, plantarflexors, and tibialis posterior. This was measured on a 5-point scale where 1 is
132 defined as a ‘visible or palpable contraction (no range of motion)’ and 5 is defined as ‘full range of
133 motion against gravity’. Again, we calculated a summary strength score using polychoric principal
134 component analysis, which included measurements from both lower limbs for individuals with
135 complete data (12 measurements total).

136 Selective motor control (SMC) was measured by a physical therapist using a 3-point scale defined by
137 the following: (0) very little or no control of a single joint voluntary movement, (1) impaired
138 voluntary movement at a single joint, and (2) good voluntary movement at a joint. The physical
139 therapist measured SMC for hip flexion, hip adduction, knee extension, knee flexion, plantarflexion,
140 and posterior tibialis. Again, we calculated a summary SMC score with the same methods used to
141 calculate summary spasticity and strength scores.

142 Patients underwent a quantitative 3D gait analysis with electromyography of the anterior tibialis,
143 lateral and medial hamstrings, gastroc-soleus, and rectus femoris muscles. Using the motion capture
144 and electromyographic data, respectively, we calculated gait deviation index (GDI) (Schwartz and
145 Rozumalski, 2008) and dynamic motor control (DMC) (Shuman et al., 2019) scores for each child.

146 Breath-to-breath oxygen consumption was measured during six minutes of overground, barefoot
147 walking around a rectangular 80-meter track (Ultima CPX, Medical Graphics Corporation, St. Paul,
148 MN, USA). Breath-to-breath oxygen consumption was also measured during the 10 minutes of
149 reclining rest that preceded the walking session. The average steady state value was calculated for
150 both periods according to the method proposed by (Schwartz, 2007). Oxygen consumption per unit
151 time was converted to power using the conversion rate of 20.1 Joules/mL O₂ (Lusk, 1924; Taylor and
152 Heglund, 1982). We then calculated net metabolic power by subtracting resting from walking values.
153 We also calculated average walking speed during the trial and recorded patient age, height, mass, and
154 sex.

155 2.3 Causal Model

156 Structural causal models are visual representations of causal assumptions that we can systematically
157 test for plausibility and query to identify confounders. Nodes represent variables, and arrows drawn
158 (or excluded) between variables indicate causal relationships (or lack thereof) between them. The
159 absence or presence of arrows can be used to determine conditional independencies implied by the

Contributors to High Metabolic Power in CP

160 causal model. By checking these independencies, we can test the plausibility of a model. And, just as
161 we can test a model's plausibility, we can also determine from the model what variables are potential
162 confounders (see Greenland & Pearl (2017) for a detailed explanation). We can then statistically
163 adjust for these potential confounders in our computational analysis to reduce potential bias (Pearl,
164 1995). It may be necessary to adjust for more than one factor. An adjustment set is the minimum set
165 of factors to adjust for when computing the causal effect of X on Y (Pearl, 1995).

166 We define causal effects as the *total* effect of X on Y. This includes both the direct (unmediated) and
167 indirect (mediated) effects of X on Y. We focused on the total effect of each factor as treatments in
168 CP rarely affect a single factor due to their inter-relatedness. For example, strength may directly
169 affect metabolic power, but it may also indirectly affect metabolic power via changes in kinematics.

170 We built a causal model for this study that represents our hypotheses and assumptions about the
171 mechanisms contributing to metabolic demand during walking (Figure 1). We created and tested the
172 proposed model using the *dagitty* package in R (Textor et al., 2016). From our causal model, we
173 determined adjustment sets that we used in our data analysis to compute the causal effects of each
174 factor on metabolic power.

175 2.4 Data Analysis

176 After obtaining adjustment sets from our causal model, we used the Bayesian additive regression
177 trees (BART) method (Chipman et al., 2010) to compute the causal effects of GDI, DMC, SMC,
178 strength, and spasticity on metabolic power. Since BART is a regression-based approach, including
179 factors from each adjustment set as predictors in the BART model adjusted for their effects and
180 reduced confounding. A causal model identifies sources of bias, but it does not provide information
181 regarding the strength or direction of a causal relationship. Thus, it was necessary to use regression
182 analysis (i.e., BART) to compute effect sizes.

183 The BART method is an excellent option to identify the magnitude of causal effects from
184 observational data in CP. The BART method demonstrates superior predictive abilities against other
185 common methods (Dorie et al., 2019) and has been successfully used in the causal inference of
186 observational data (Hill, 2011). Many observational studies make linear assumptions. CP is a
187 complex condition, and although linear or multiple linear regression are convenient and easy-to-
188 understand tools, it is unwise to assume linearity between factors. For example, as a child's tibial
189 torsion increases (either internally or externally), we can expect their walking pattern to deteriorate,
190 resulting in a U-shaped relationship. Besides its predictive prowess, BART is a non-parametric tool
191 that a) uses Bayesian methods to produce estimates with honest uncertainty bounds in its predictions,
192 b) can handle large numbers of predictor variables of various types (scale, ordinal, categorical), c)
193 requires little-to-no hand-tuning, and d) does not require investigator involvement to determine the
194 shape of the response surface (Hill, 2011). In addition, BART natively handles missing data
195 (increasing sample representativeness) and outperforms imputation methods when dealing with data
196 not missing at random (Kapelner and Bleich, 2015).

197 To visualize and interpret the causal effects specified by our BART models, we utilized accumulated
198 local effects plots (Apley and Zhu, 2020). These plots show the average change in the response
199 variable (i.e., metabolic power) due to changes in the predictor variable (i.e., GDI, DMC, SMC,
200 strength, or spasticity). Machine learning algorithms, such as BART, are harder to interpret than
201 linear regression because they use more complex (and often hidden) functions. By visualizing the
202 results, we could interpret the causal effects specified by our model. Accumulated local effects plots,

Contributors to High Metabolic Power in CP

203 in particular, are unbiased when features are highly correlated compared to other visualization
204 methods, such as partial dependence plots (Apley and Zhu, 2020).

205 We used the R package *bartMachine* (Kapelner and Bleich, 2015) to create our BART models.
206 Following hyperparameter optimization, the model settings were: $num_trees = 50$, $k = 5$, $nu = 3$, $q =$
207 0.99 , $use_missing_data = TRUE$. For replicability, we set the seed of each model as 42. To visualize
208 the causal effects of each factor in the form of accumulated local effects plots, we used the R package
209 *ALEPlot* (Apley, 2018). From each plot, we approximated effect sizes using the range of the middle
210 95th percentile of the sample.

211 3 Results

212 3.1 Participants

213 We analyzed data from 2157 children who met our inclusion criteria (Table 1). Of those children,
214 32.1% were missing DMC scores, 18.3% were missing spasticity scores, 17.7% were missing
215 strength scores, 17.5% were missing SMC scores, and 0.6% were missing GDI scores.

216 3.2 Outcomes of Causal Model

217 Our model satisfied all implied conditional independencies. The conventional cut-off for
218 independence is ± 0.3 . All partial correlation coefficients were smaller than ± 0.2 , suggesting that the
219 observed data was consistent with the proposed relationships in our causal model (i.e., our model was
220 plausible). From our model, we obtained sufficient adjustment sets for all variables (Table 2).
221 Adjustment sets were the same for DMC, SMC, spasticity and strength.

222 3.3 Outcomes of BART

223 The purpose of this project was to determine the causal effects of GDI, DMC, SMC, strength and
224 spasticity on metabolic power. Based on the adjustment sets indicated by our assumed causal model,
225 we only required two BART models: one to compute the effects of GDI ($r^2 = 0.81$, $rmse = 32.96$) and
226 one to compute the effects of DMC, SMC, strength and spasticity ($r^2 = 0.72$, $rmse = 39.48$). From the
227 accumulated local effects plots (Figure 2), we approximated effect sizes using the range of the middle
228 95th percentile of the sample (Figure 3). GDI had approximately a two-fold effect on metabolic
229 power than DMC, SMC and spasticity. Strength had the smallest effect on metabolic power. These
230 results indicate that gait kinematics had the largest effect on high metabolic power.

231 The GDI had the steepest curve (Figure 2), on average, suggesting that changing GDI can elicit the
232 largest changes in metabolic power. Most of the factors shared a near-linear or sigmoidal relationship
233 with metabolic power. However, strength and metabolic power shared an almost inverted-U
234 relationship. Regardless of shape, most factors plateaued at the extremes of each plot. These plateaus
235 suggest that after a certain level of impairment, metabolic power may not increase or decrease
236 considerably. So, children with mild or very severe level impairments may experience limited
237 reductions in metabolic power following treatment. For example, children with largely in-tact
238 dynamic motor control may experience limited changes in metabolic power due to ceiling effects
239 whereas, children with severely compromised DMC may experience limited changes in metabolic
240 power due to movement limitations.

241 4 Discussion

Contributors to High Metabolic Power in CP

242 Reducing metabolic power is a means of reducing fatigue and facilitating physical activity in children
243 with CP. Our analysis indicates that gait kinematics (as quantified by GDI) had the largest causal
244 effect on metabolic power, more than twice as large as the other factors. The effects of SMC, DMC
245 and spasticity had the next largest contributions to metabolic power. Strength had the smallest effect.
246 These results suggest that improving gait kinematics may elicit reductions in metabolic power that
247 are more likely to be clinically meaningful.

248 On average, children with CP need to reduce their metabolic power by 50% to achieve values within
249 the typical range. Such a reduction may not be possible, but a 10% reduction in metabolic power is
250 still considered clinically meaningful (Oeffinger et al., 2008). This value can be used to interpret the
251 observed effects in this study.

252 We cannot perform randomized control trials, but we must assess the order of magnitude of our
253 results to either confirm or refute our findings. The model-predicted changes in metabolic power
254 following changes in GDI are comparable to experimental studies. In the study by McMulkin et al.,
255 children (GMFCS level I/II) who underwent surgical intervention with a femoral derotation
256 osteotomy improved their GDI by ~13 points and their net oxygen cost (net volume of oxygen
257 consumed per unit distance) by ~15% (McMulkin et al., 2016). According to our results, metabolic
258 power would decrease by 12-27W if GDI increased by 13 points. For a child with median metabolic
259 power in our sample (124W), this would be equivalent to a 10-22% decrease in metabolic power. The
260 values seen by McMulkin et al. fall within this range. In another study, children with CP improved
261 their GDI by approximately five points and their net oxygen cost by 2.5% one year following
262 surgical intervention (Wren et al., 2013). According to our results, metabolic power would change by
263 2-13% for a child with the median metabolic power if the GDI increases by five points. While our
264 estimates seem high, Wren et al. may have found insignificant results because their sample included
265 children with more severe CP (i.e., GMFCS level IV). Children with more severe impairments (i.e.,
266 GMFCS level III and IV) have significantly greater metabolic power during walking (Bolster et al.,
267 2017). So, even if they experience similar *absolute* reductions in metabolic power, *relative* reductions
268 in metabolic power may not be as significant because metabolic power is higher overall. This may be
269 why Wren et al. saw lower changes than those predicted by our results. Further, McMulkin et al. only
270 saw significant reductions in metabolic power for children with GMFCS level I/II despite greater
271 *absolute* reductions in metabolic power for children with GMFCS level III. Thus, treatments that
272 produce greater changes in gait kinematics may yield more significant results for children with lower
273 metabolic power when we consider relative rather than absolute changes.

274 This research highlights how myriad factors impact metabolic power in CP, which can provide
275 numerous pathways for potentially improving walking power. Our model suggests that changes in
276 GDI and motor control affect metabolic power. Interventions that can improve these factors may
277 improve metabolic power. This was recently observed in a pilot study by Conner et al. A small group
278 of children with CP improved DMC by 7% and reduced metabolic power by 29% after resistance
279 training with an ankle exoskeleton (Conner et al., 2021). According to our results, metabolic power
280 should decrease by 1-11% for a 7% improvement in DMC. These estimates are lower than Conner et
281 al., but Conner et al. have also shown that their exoskeleton training results in mechanically more
282 efficient gait (Conner et al., 2021) and significantly greater muscle strength (Conner et al., 2020).
283 Since our model does not include a metric of gait kinetics, this could have affected our causal effect
284 estimates. In addition, a large proportion of children in our sample (31.2%) are missing DMC scores.
285 Although BART natively handles missing data, greater missing data increases model uncertainty.
286 Both unexplained factors and model uncertainty might explain why our estimates are lower. We
287 estimate SMC has similar effects on metabolic power as DMC. SMC and DMC are only moderately

Contributors to High Metabolic Power in CP

288 correlated ($r = 0.54$), which suggests that although both are related, they also explain different aspects
289 of motor control in CP. Thus, the treatment of children with CP should include both selective and
290 dynamic motor control training.

291 Despite modest total effects, spasticity itself may not be a large contributor to high metabolic power.
292 In a study by Zaino et al. (2020), children who underwent selective dorsal rhizotomy experienced a
293 0.9 point reduction in lower body spasticity (approximately a change of one level out of four
294 typically seen) and a 12% reduction in metabolic power, on average. For the same reduction in
295 spasticity, our results indicate that metabolic power should decrease by 2-14% for a child with the
296 median metabolic power. Our estimates capture the values found by Zaino et al. Similar to Zaino's
297 study, our results reflect the total effect of spasticity on metabolic power. Total effects include
298 indirect effects, such as those associated with changes to gait kinematics, so spasticity alone may not
299 be an important determinant of metabolic power. To further support this point, Zaino et al. found
300 changes in metabolic power were not significantly different when compared to a control group, and
301 when we calculate the direct effect of spasticity, it is only a third of its total effect. Therefore, other
302 factors may be responsible for meaningful reductions in metabolic power following spasticity
303 reduction.

304 Compared to the other variables assessed in this study, strength has smaller causal effects and
305 training strength is not likely to cause meaningful reductions in metabolic power. With a single
306 standard deviation change in strength, our model predicts that metabolic power changes by 1-7% for
307 the average child in our sample. While this may seem like a small reduction, it is not entirely
308 unexpected. As a result of strength training, children with CP often walk faster and for longer
309 distances (Damiano and Abel, 1998; Eagleton et al., 2004). Since walking faster ultimately increases
310 metabolic power, it would explain why strength has a smaller total effect on metabolic power.
311 Interestingly, strength shares a slight inverted-U-shaped relationship with metabolic power. Weaker
312 individuals may experience increased metabolic power after strength training because they can walk
313 longer and faster. And stronger individuals may experience decreased metabolic power after strength
314 training because their motor control has improved along with their strength, so they can walk more
315 efficiently. Other studies have also speculated that different responses to strength training arise due to
316 changes in walking speed and mechanical efficiency (Damiano and Abel, 1998; Eagleton et al.,
317 2004). But, although metabolic power may not change drastically, strength training is still important
318 for improving other functional outcomes important to children with CP (Conner et al., 2020).

319 We did not normalize or non-dimensionalize metabolic power. We made this choice to simplify our
320 causal model and avoid spurious relationships caused by imperfect normalization. Most non-
321 dimensionalization schemes assume a linear dependence of metabolic power on mass. While this
322 assumption holds true in typically developed populations, it may not apply to children with CP. A
323 study by Plasschaert et al. simulated weight gain during walking in children with and without CP –
324 they noticed that mass normalization was not as effective in removing mass-dependence for the
325 children with CP (Plasschaert et al., 2008). We noticed a similar phenomenon in our data. This
326 suggests that mass and metabolic power share a non-linear relationship in children with CP. If this is
327 true, decreases in mass may elicit greater reductions in metabolic power for a child with CP than a
328 typically developed child. The opposite would also be true, and both would have important
329 implications for weight management in children with CP.

330 Our model, like all models, requires assumptions. An advantage of structural causal models is that
331 the assumptions are made clear and explicit, and the plausibility of those assumptions is tested. So,
332 while our model may not perfectly represent the causes of high metabolic power in CP, by explicitly

Contributors to High Metabolic Power in CP

333 specifying our causal assumptions, researchers will be able to compare their results and models. We
334 believe our causal model is a valuable starting point and will lead to experimental research that
335 accepts or rejects hypotheses informed by these results.

336 Reducing metabolic power can play an important role in reducing or delaying fatigue onset in
337 children with CP and allowing them to be more physically active. Using large-scale data spanning a
338 diverse study sample of widely varying age, GMFCS level, and CP subtype, we sought to understand
339 the causal effects of commonly treated variables (i.e., GDI, SMC, DMC, spasticity, and strength) on
340 metabolic power. Our findings suggest that impaired gait kinematics contribute the most to high
341 metabolic power, followed by SMC and DMC. If the primary goal of treatment is to reduce fatigue,
342 improving motor control and gait mechanics may be the most effective treatment options. Future
343 research should look to perform controlled experiments to test the legitimacy of these findings.

344 **5 Conflict of Interest**

345 The authors declare that the research was conducted in the absence of any commercial or financial
346 relationships that could be construed as a potential conflict of interest.

347 **6 Author Contributions**

348 P.K.G., K.M.S., J.M.D., and M.H.S. conceived and designed the research; P.K.G. analyzed the data,
349 prepared figures, and drafted the manuscript; P.K.G., K.M.S., J.M.D., and M.H.S. interpreted the
350 results, revised the manuscript, and approved the final version of the manuscript.

351 **7 Funding**

352 This work was supported by a Canadian Graduate Scholarship (Master's) from the Natural Sciences
353 and Engineering Research Council of Canada (NSERC) and the Eunice Kennedy Shriver National
354 Institute of Child Health & Human Development of the National Institutes of Health under award
355 number R21HD104112.

356 **8 References**

- 357 Apley, D. (2018). *ALEPlot: Accumulated Local Effects (ALE) Plots and Partial Dependence (PD)*
358 *Plots. R package version 1.1*. Available at: <https://CRAN.R-project.org/package=ALEPlot>.
- 359 Apley, D. W., and Zhu, J. (2020). Visualizing the effects of predictor variables in black box
360 supervised learning models. *J. R. Stat. Soc. Series B Stat. Methodol.* 82, 1059–1086.
361 doi:10.1111/rssb.12377.
- 362 Balemans, A. C., Bolster, E. A., Brehm, M.-A., and Dallmeijer, A. J. (2017). Physical Strain: A New
363 Perspective on Walking in Cerebral Palsy. *Arch. Phys. Med. Rehabil.* 98, 2507–2513.
364 doi:10.1016/j.apmr.2017.05.004.
- 365 Bennett, B. C., Russell, S. D., and Abel, M. F. (2012). The effects of ankle foot orthoses on energy
366 recovery and work during gait in children with cerebral palsy. *Clin. Biomech.* 27, 287–291.
367 doi:10.1016/j.clinbiomech.2011.09.005.

Contributors to High Metabolic Power in CP

- 368 Bjornson, K., Hays, R., Graubert, C., Price, R., Won, F., McLaughlin, J. F., et al. (2007). Botulinum
369 toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. *Pediatrics*
370 120, 49–58. doi:10.1542/peds.2007-0016.
- 371 Bohannon, R. W., and Smith, M. B. (1987). Interrater reliability of a modified Ashworth scale of
372 muscle spasticity. *Phys. Ther.* 67, 206–207. doi:10.1093/ptj/67.2.206.
- 373 Bolster, E. A. M., Balemans, A. C. J., Brehm, M.-A., Buizer, A. I., and Dallmeijer, A. J. (2017).
374 Energy cost during walking in association with age and body height in children and young
375 adults with cerebral palsy. *Gait Posture* 54, 119–126. doi:10.1016/j.gaitpost.2017.02.026.
- 376 Campbell, J., and Ball, J. (1978). Energetics of walking in cerebral palsy. *Orthop. Clin. North Am.* 9,
377 374–377. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/662304>.
- 378 Carlon, S. L., Taylor, N. F., Dodd, K. J., and Shields, N. (2013). Differences in habitual physical
379 activity levels of young people with cerebral palsy and their typically developing peers: a
380 systematic review. *Disabil. Rehabil.* 35, 647–655. doi:10.3109/09638288.2012.715721.
- 381 Chipman, H. A., George, E. I., and McCulloch, R. E. (2010). BART: BAYESIAN ADDITIVE
382 REGRESSION TREES. *Ann. Appl. Stat.* 4, 266–298. Available at:
383 <http://www.jstor.org/stable/27801587>.
- 384 Conner, B. C., Remec, N. M., Orum, E. K., Frank, E. M., and Lerner, Z. F. (2020). Wearable
385 Adaptive Resistance Training Improves Ankle Strength, Walking Efficiency and Mobility in
386 Cerebral Palsy: A Pilot Clinical Trial. *IEEE Open J Eng Med Biol* 1, 282–289.
387 doi:10.1109/ojemb.2020.3035316.
- 388 Conner, B. C., Schwartz, M. H., and Lerner, Z. F. (2021). Pilot evaluation of changes in motor
389 control after wearable robotic resistance training in children with cerebral palsy. *J. Biomech.*
390 126, 110601. doi:10.1016/j.jbiomech.2021.110601.
- 391 Damiano, D. L., and Abel, M. F. (1998). Functional outcomes of strength training in spastic cerebral
392 palsy. *Arch. Phys. Med. Rehabil.* 79, 119–125. doi:10.1016/s0003-9993(98)90287-8.
- 393 Damiano, D. L., Martellotta, T. L., Sullivan, D. J., Granata, K. P., and Abel, M. F. (2000). Muscle
394 force production and functional performance in spastic cerebral palsy: relationship of
395 cocontraction. *Arch. Phys. Med. Rehabil.* 81, 895–900. doi:10.1053/apmr.2000.5579.
- 396 Dorie, V., Hill, J., Shalit, U., Scott, M., and Cervone, D. (2019). Automated versus Do-It-Yourself
397 Methods for Causal Inference: Lessons Learned from a Data Analysis Competition. *SSO*
398 *Schweiz. Monatsschr. Zahnheilkd.* 34, 43–68. doi:10.1214/18-STS667.
- 399 Eagleton, M., Iams, A., McDowell, J., Morrison, R., and Evans, C. L. (2004). The effects of strength
400 training on gait in adolescents with cerebral palsy. *Pediatr. Phys. Ther.* 16, 22–30.
401 doi:10.1097/01.PEP.0000116781.00415.8E.
- 402 Gross, P. H., Bailes, A. F., Horn, S. D., Hurvitz, E. A., Kean, J., Shusterman, M., et al. (2018).
403 Setting a patient-centered research agenda for cerebral palsy: a participatory action research
404 initiative. *Dev. Med. Child Neurol.* 60, 1278–1284. doi:10.1111/dmcn.13984.

Contributors to High Metabolic Power in CP

- 405 Hammam, N., Becher, H., Andersen, J., Manns, P. J., Whittaker, J. L., and Pritchard, L. (2021). Early
406 indicators of cardiovascular disease are evident in children and adolescents with cerebral
407 palsy. *Disabil. Health J.*, 101112. doi:10.1016/j.dhjo.2021.101112.
- 408 Hernán, M. A., and Robins, J. M. (2020). *Causal inference: What if*. Boca Raton: Chapman &
409 Hall/CRC.
- 410 Hill, J. L. (2011). Bayesian Nonparametric Modeling for Causal Inference. *J. Comput. Graph. Stat.*
411 20, 217–240. doi:10.1198/jcgs.2010.08162.
- 412 Jahnsen, R., Villien, L., Stanghelle, J. K., and Holm, I. (2007). Fatigue in adults with cerebral palsy
413 in Norway compared with the general population. *Dev. Med. Child Neurol.* 45, 296–303.
414 doi:10.1111/j.1469-8749.2003.tb00399.x.
- 415 Kapelner, A., and Bleich, J. (2015). Prediction with missing data via Bayesian Additive Regression
416 Trees. *Can. J. Stat.* 43, 224–239. doi:10.1002/cjs.11248.
- 417 Kolenikov, S., and Angeles, G. (2009). Socioeconomic status measurement with discrete proxy
418 variables: Is principal component analysis a reliable answer? *Rev. Income Wealth* 55, 128–
419 165. doi:10.1111/j.1475-4991.2008.00309.x.
- 420 Lusk, G. (1924). Animal calorimetry. *J. Biol. Chem.* 59, 41–42. doi:10.1016/s0021-9258(18)85293-
421 0.
- 422 MacPhail, H. E., and Kramer, J. F. (1995). Effect of isokinetic strength-training on functional ability
423 and walking efficiency in adolescents with cerebral palsy. *Dev. Med. Child Neurol.* 37, 763–
424 775. doi:10.1111/j.1469-8749.1995.tb12060.x.
- 425 MacWilliams, B. A., Prasad, S., Shuckra, A. L., and Schwartz, M. H. (2020). Causal factors affecting
426 gross motor function in children diagnosed with cerebral palsy. [Preprint]. *bioRxiv*.
427 doi:10.1101/2020.10.26.20217232.
- 428 McMulkin, M. L., Gordon, A. B., Caskey, P. M., Tompkins, B. J., and Baird, G. O. (2016).
429 Outcomes of Orthopaedic Surgery With and Without an External Femoral Derotational
430 Osteotomy in Children With Cerebral Palsy. *J. Pediatr. Orthop.* 36, 382–386.
431 doi:10.1097/BPO.0000000000000465.
- 432 Munger, M. E., Aldahondo, N., Krach, L. E., Novacheck, T. F., and Schwartz, M. H. (2017). Long-
433 term outcomes after selective dorsal rhizotomy: a retrospective matched cohort study. *Dev.*
434 *Med. Child Neurol.* 59, 1196–1203. doi:10.1111/dmcn.13500.
- 435 Odding, E., Roebroek, M. E., and Stam, H. J. (2006). The epidemiology of cerebral palsy:
436 incidence, impairments and risk factors. *Disabil. Rehabil.* 28, 183–191.
437 doi:10.1080/09638280500158422.
- 438 Oeffinger, D., Bagley, A., Rogers, S., Gorton, G., Kryscio, R., Abel, M., et al. (2008). Outcome tools
439 used for ambulatory children with cerebral palsy: responsiveness and minimum clinically
440 important differences. *Dev. Med. Child Neurol.* 50, 918–925. doi:10.1111/j.1469-
441 8749.2008.03150.x.

Contributors to High Metabolic Power in CP

- 442 Pandyan, A. D., Johnson, G. R., Price, C. I., Curless, R. H., Barnes, M. P., and Rodgers, H. (1999). A
443 review of the properties and limitations of the Ashworth and modified Ashworth Scales as
444 measures of spasticity. *Clin. Rehabil.* 13, 373–383. doi:10.1191/026921599677595404.
- 445 Pearl, J. (1995). Causal Diagrams for Empirical Research. *Biometrika* 82, 669–688.
446 doi:10.2307/2337329.
- 447 Plasschaert, F., Jones, K., and Forward, M. (2008). The effect of simulating weight gain on the
448 energy cost of walking in unimpaired children and children with cerebral palsy. *Arch. Phys.
449 Med. Rehabil.* 89, 2302–2308. doi:10.1016/j.apmr.2008.05.023.
- 450 Rose, J., Gamble, J. G., Burgos, A., Medeiros, J., and Haskell, W. L. (1990). Energy expenditure
451 index of walking for normal children and for children with cerebral palsy. *Dev. Med. Child
452 Neurol.* 32, 333–340. doi:10.1111/j.1469-8749.1990.tb16945.x.
- 453 Rose, J., and McGill, K. C. (2007). Neuromuscular activation and motor-unit firing characteristics in
454 cerebral palsy. *Dev. Med. Child Neurol.* 47, 329–336. doi:10.1111/j.1469-
455 8749.2005.tb01144.x.
- 456 Rozumalski, A., and Schwartz, M. H. (2009). Crouch gait patterns defined using k-means cluster
457 analysis are related to underlying clinical pathology. *Gait Posture* 30, 155–160.
458 doi:10.1016/j.gaitpost.2009.05.010.
- 459 Ryan, J. M., Hensey, O., McLoughlin, B., Lyons, A., and Gormley, J. (2014). Reduced moderate-to-
460 vigorous physical activity and increased sedentary behavior are associated with elevated
461 blood pressure values in children with cerebral palsy. *Phys. Ther.* 94, 1144–1153.
462 doi:10.2522/ptj.20130499.
- 463 Ryan, J. M., Lavelle, G., Theis, N., Noorkoiv, M., Kilbride, C., Korff, T., et al. (2020). Progressive
464 resistance training for adolescents with cerebral palsy: the STAR randomized controlled trial.
465 *Dev. Med. Child Neurol.* 62, 1283–1293. doi:10.1111/dmcn.14601.
- 466 Schwartz, M. H. (2007). Protocol changes can improve the reliability of net oxygen cost data. *Gait
467 Posture* 26, 494–500. doi:10.1016/j.gaitpost.2007.07.014.
- 468 Schwartz, M. H., and Rozumalski, A. (2008). The Gait Deviation Index: a new comprehensive index
469 of gait pathology. *Gait Posture* 28, 351–357. doi:10.1016/j.gaitpost.2008.05.001.
- 470 Schwartz, M. H., Rozumalski, A., and Steele, K. M. (2016). Dynamic motor control is associated
471 with treatment outcomes for children with cerebral palsy. *Dev. Med. Child Neurol.* 58, 1139–
472 1145. doi:10.1111/dmcn.13126.
- 473 Shuman, B. R., Goudriaan, M., Desloovere, K., Schwartz, M. H., and Steele, K. M. (2019). Muscle
474 synergies demonstrate only minimal changes after treatment in cerebral palsy. *J. Neuroeng.
475 Rehabil.* 16, 46. doi:10.1186/s12984-019-0502-3.
- 476 Steele, K. M., Rozumalski, A., and Schwartz, M. H. (2015). Muscle synergies and complexity of
477 neuromuscular control during gait in cerebral palsy. *Dev. Med. Child Neurol.* 57, 1176–1182.
478 doi:10.1111/dmcn.12826.

Contributors to High Metabolic Power in CP

- 479 Taylor, C. R., and Heglund, N. C. (1982). Energetics and mechanics of terrestrial locomotion. *Annu.*
480 *Rev. Physiol.* 44, 97–107. doi:10.1146/annurev.ph.44.030182.000525.
- 481 Textor, J., van der Zander, B., Gilthorpe, M. S., Liskiewicz, M., and Ellison, G. T. (2016). Robust
482 causal inference using directed acyclic graphs: the R package “dagitty.” *Int. J. Epidemiol.* 45,
483 1887–1894. doi:10.1093/ije/dyw341.
- 484 Thomas, S. S., Buckon, C. E., Piatt, J. H., Aiona, M. D., and Sussman, M. D. (2004). A 2-year
485 follow-up of outcomes following orthopedic surgery or selective dorsal rhizotomy in children
486 with spastic diplegia. *J. Pediatr. Orthop. B* 13, 358–366. doi:10.1097/01202412-200411000-
487 00002.
- 488 Ubhi, T., Bhakta, B. B., Ives, H. L., Allgar, V., and Roussounis, S. H. (2000). Randomised double
489 blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.
490 *Arch. Dis. Child.* 83, 481–487. doi:10.1136/adc.83.6.481.
- 491 Verschuren, O., Wiart, L., Hermans, D., and Ketelaar, M. (2012). Identification of facilitators and
492 barriers to physical activity in children and adolescents with cerebral palsy. *J. Pediatr.* 161,
493 488–494. doi:10.1016/j.jpeds.2012.02.042.
- 494 Wren, T. A. L., Otsuka, N. Y., Bowen, R. E., Scaduto, A. A., Chan, L. S., Dennis, S. W., et al.
495 (2013). Outcomes of lower extremity orthopedic surgery in ambulatory children with cerebral
496 palsy with and without gait analysis: results of a randomized controlled trial. *Gait Posture* 38,
497 236–241. doi:10.1016/j.gaitpost.2012.11.018.
- 498 Zaino, N. L., Steele, K. M., Donelan, J. M., and Schwartz, M. H. (2020). Energy consumption does
499 not change after selective dorsal rhizotomy in children with spastic cerebral palsy. *Dev. Med.*
500 *Child Neurol.* 62, 1047–1053. doi:10.1111/dmcn.14541.

501

Contributors to High Metabolic Power in CP




Figure 1. Causal model (portrayed as a directed acyclic graph) of the potential contributors to high metabolic power during walking in children with cerebral palsy (CP). The initial brain injury is colored white to represent an unmeasured factor. Despite being unmeasured, including the initial brain injury helps to simplify the complex relationship between neurological impairments in CP. Blue nodes are factors often treated and measured in the clinic (neurological and physical impairments), so understanding their effects offers a better understanding of their importance in treating metabolic power. Metabolic power, colored in black, is the outcome of interest. Gray variables are potential confounders.

502

503

Contributors to High Metabolic Power in CP

Table 1. Participant Characteristics

	Total	GMFCS I	GMFCS II	GMFCS III
n (%)	2157	662 (30.7%)	1000 (46.4%)	495 (22.9%)
Sex = male (%)	1212 (56.2%)	375 (56.6%)	552 (55.2%)	285 (57.6%)
Age (median (SD))	9.3 (3.7)	10.1 (3.5)	8.8 (3.7)	8.2 (3.7)
Height (median (SD))	129.5 (20.3)	136.5 (18.8)	127.5 (20.4)	119.9 (19.4)
Mass (median (SD))	26.9 (15.8)	31.4 (16.1)	26.5 (15.9)	23.5 (14.6)
GDI (median (SD))	71.1 (12.5)	80.0 (10.3)	70.9 (11.1)	60.7 (9.2)
DMC (median (SD))	83.3 (9.9)	90.3 (8.0)	81.7 (8.7)	74.1 (8.3)
SMC (median (SD))	0.25 (1.1)	0.88 (0.7)	0.13 (1.0)	-1.11 (1.0)
Spasticity (median (SD))	-0.25 (1.1)	-0.52 (0.7)	-0.16 (1.1)	0.36 (1.3)
Strength (median (SD))	0.16 (1.1)	0.85 (0.7)	0.08 (0.9)	-1.15 (0.9)
Met. Power (median (SD))	124.2 (75.3)	119.9 (66.9)	127.5 (77.2)	120.1 (81.2)

Height is described in cm. Mass is described in kg. SMC, spasticity, and strength are scores derived from polychoric principal component analysis.

504

Table 2. Adjustment sets necessary to minimize confounding bias

	Adjustment Set
GDI	Walking speed, DMC, SMC, spasticity, strength, age, height, mass
DMC	SMC, spasticity, strength, age, height mass
SMC	DMC, spasticity, strength, age, height, mass
Spasticity	DMC, SMC, strength, age, height, mass
Strength	DMC, SMC, spasticity, age, height, mass

505

506

Contributors to High Metabolic Power in CP




Figure 2. Accumulated local effects plot of the total causal effects of gait deviation index, selective motor control, dynamic motor control, spasticity, and strength on metabolic power with 95% bootstrapped confidence intervals. These plots represent the average change in metabolic power that can be expected with a change in the x-variable. X-axis variables are normalized as z-scores, where increasing or more positive scores indicate a lesser severity of impairment (i.e., more typical gait, more coordinated, less spastic, stronger). Rug plots along the x-axis display the distribution of scores for each impairment. The bottom right scale indicates how large a single standard deviation is with respect to original units.

507




Figure 3. The range of the causal effect for each factor for the middle 95th percentile. The dotted and dashed lines show the 25th percentile and median metabolic power of children included in this study. The total effect of GDI is approximately twice that of SMC and DMC, and more than thrice that of spasticity or strength.

508

509